Myelodysplastic syndrome hematopoietic stem cell

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 525-533

  Li, June ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CD34+ cell; cell signaling pathway; hematopoietic stem cell; MiRNA; myelodysplastic syndrome

Indexed keywords

BETA CATENIN; CD19 ANTIGEN; CD33 ANTIGEN; CD38 ANTIGEN; CD7 ANTIGEN; CD79 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DNA DIRECTED DNA POLYMERASE GAMMA; HERMES ANTIGEN; HISTONE DEACETYLASE 5; INTERLEUKIN 3; INTERLEUKIN 7 RECEPTOR; LYMPHOID ENHANCER FACTOR 1; MICRORNA; NUCLEOPHOSMIN; PROTEIN MDM2; PROTEIN TYROSINE PHOSPHATASE; RAG2 PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SOS PROTEIN; STAT1 PROTEIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; WNT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; CD34 SELECTION; CELL DIFFERENTIATION; CELL LINEAGE; CHROMOSOME 5Q; CHROMOSOME DELETION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPLICEOSOME; STEM CELL NICHE; TRISOMY 8; UPREGULATION;

ANTIGENS, CD34; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84878010841     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27896     Document Type: Review

References (112)

1. Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-29.
2. Aul C, Giagounidis A, Germing U,. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001; 73: 405-10.
3. Komrokji R,. Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk Res 2006; 30: 1067-8.
4. Aivado M, Iwanaga M, Miyazaki Y, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106: 2633-40.
5. Lübbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 2001; 114: 349-57.
6. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40.
7. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-7.
8. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009; 15: 5002-7.
9. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q). N Engl J Med 2010; 363: 1025-37.
10. Bernasconi P,. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 2008; 142: 695-708.
11. McCulloch EA,. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood 1983; 62: 1-13.
12. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994; 367: 645-48.
13. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-37.
14. Jordan CT,. The leukemic stem cell. Best Pract Res Clin Haematol 2007; 20: 13-8.
15. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-53.
16. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 2012.
17. Benito AI, Bryant E, Loken MR, et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 2003; 27: 425.
18. Thanopoulou E, Cashman J, Kakagianne T, et al. Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004; 103: 4285.
19. Kerbauy DM, Lesnikov V, Torok-Storb B, et al. Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin- deficient mice after intramedullary transplantation of hematopoietic and stromal cells. Blood 2004; 104: 2202.
20. Phillips RL, Ernst RE, Brunk B, et al. The genetic program of hematopoietic stem cells. Science 2000; 288: 1635-40.
21. Nilsson L, Åstrand-Grundström I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2002; 96: 2012-21.
22. Nilsson L, Edén P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q- myelodysplastic syndromes. Blood 2007; 110: 3005-14.
23. Chung YJ, Choi CW, Slape C, et al. Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. Proc Natl Acad Sci USA 2008; 105: 14088-93.
24. Nimer SD,. MDS: a stem cell disorder-but what exactly is wrong with the primitive hematopoietic cells in this disease? In:, Burns LJ, Mikhael JR, Schwartz BS, Crowther MA,. Hematology. Washington, DC: American Society of Hematology, 2008: 43-51.
25. Galy A, Travis M, Cen D, et al. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3: 459-73.
26. Kondo M, Weissman IL, Akashi K,. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 1997; 91: 661-72.
27. Buckton KE, Brown WM, Smith PG,. Lymphocyte survival in men treated with x-rays for ankylosing spondylitis. Nature 1967; 214: 470-73.
28. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005; 106: 2982-91.
29. Olney HJ, Le Beau MM,. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001; 14: 479-95.
30. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-95.
31. Prall WC, Czibere A, Grall F, et al. Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. Int J Hematol 2009; 89: 173-87.
32. Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004; 104: 4210-8.
33. Hofmann WK, de Vos S, Komor M, et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 3553-60.
34. Miyazato A, Ueno S, Ohmine K, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001; 98: 422-7.
35. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
36. Nam D, Kim S,. Gene-set approach for expression pattern analysis. Brief Bioinform 2008; 9: 189-97.
37. Ein-Dor L, Kela I, Getz G, et al. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2005; 21: 171-8.
38. Bild A, Potti A, Nevins J,. Opinion: linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006; 6: 735-41.
39. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010; 24: 756-64.
40. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92: 3234-8.
41. Yamazaki S, Nakauchi H,. Insights into signaling and function of hematopoietic stem cells at the single-cell level. Curr Opin Hematol 2009; 16: 255-8.
42. Bellini O, Casazza AM, di Marco A,. Histological and histochemical studies of myocardial lesions in BALBc/Cr mice. Lab Anim Sci 1976; 26: 329-33.
43. Bindra RS, Glazer PM,. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007; 26: 2048-57.
44. Garuti G, Genazzani AR,. Human neu oncogene is expressed in endometrial but not in ovarian adenocarcinomas. Cancer 1991; 67: 1713.
45. Welch JS, Link DC,. Genomics of AML: clinical applications of next-generation sequencing. Hematol Am Soc Hematol Educ Program 2011; 2011: 30-5.
46. Dostalova Merkerova M, Krejcik Z, Votavova H, et al. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011; 19: 313-9.
47. Votavova H, Grmanova M, Dostalova Merkerova M, et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011; 4: 1-6.
48. Pons A, Nomdedeu B, Navarro A, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009; 50: 1854-9.
49. Hussein K, Theophile K, Busche G, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010; 34: 1169-74.
50. Sokol L, Caceres G, Volinia S, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011; 153: 24-32.
51. Erdogan B, Facey C, Qualtieri J, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011; 39: 915-26.
52. Hussein K, Busche G, Muth M, et al. Expression of myelopoiesis-associated microRNA in bone marrow cells of atypical chronic myeloid leukaemia and chronic myelomonocytic leukaemia. Ann Hematol 2010; 90: 307-13.
53. + hematopoietic stem/progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-5.
54. O'Connell RM, Rao D, Chaudhuri A, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008; 205: 585-94.
55. Lu J, Guo S, Ebert B, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008; 14: 843-53.
56. Liao R, Sun J, Zhang L, et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 2008; 104: 805-17.
57. Goff LA, Boucher S, Ricupero CL, et al. Differentiating human multipotent mesenchymal stromal cells regulate microRNAs: prediction of microRNA regulation by PDGF during osteogenesis. Exp Hematol 2008; 36: 1354-69.
58. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA 2006; 103: 5078-83.
59. Barroga CF, Pham H, Kaushansky K,. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 2008; 36: 1585-92.
60. Xiao C, Calado DP, Galler G, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131: 146-59.
61. Zhou B, Wang S, Mayr C, et al. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 2007; 104: 7080-85.
62. Ben-Ami O, Pencovich N, Lotem J, et al. A regulatory interplay between miR-27 a° and Runx1 during megakaryopoiesis. Proc Natl Acad Sci USA 2009; 106: 238-43.
63. Romania P, Lulli V, Pelosi E, et al. MicroRNA155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. Br J Haematol 2008; 143: 570-80.
64. Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146°/CXCR4 control megakaryopoiesis. Nat Cell Biol 2008; 10: 788-801.
65. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT,. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007; 35: 1657-67.
66. Zhan M, Miller CP, Papayannopoulou T, et al. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol 2007; 35: 1015-25.
67. Kosaka N, Sugiura K, Yamamoto Y, et al. Identification of erythropoietin-induced microRNAs in hematopoietic cells during erythroid differentiation. Br J Haematol 2008; 142: 293-300.
68. Choong ML, Yang HH, McNiece I,. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol 2007; 35: 551-64.
69. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythropoiesis and erythroleukemic cell growth via kit receptor down- modulation. Proc Natl Acad Sci USA 2005; 102: 18081-6.
70. Dore L, Amigo JD, Dos Santos CO, et al. A GATA-1 regulated miRNA locus essential for erythropoiesis. Proc Natl Acad Sci USA 2008; 105: 3333-8.
71. Fu YF, Du TT, Dong M, et al. Mir-144 selectively regulates embryonic α-hemoglobin synthesis during primitive erythropoiesis. Blood 2009; 113: 1340-9.
72. Wang Q, Huang Z, Xue H, et al. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type receptor ALK4. Blood 2008; 111: 588-95.
73. Fazi A, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123: 819-31.
74. Velu CS, Baktula AM, Grimes HL,. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009; 113: 4720-8.
75. Feng J, Iwama A, Masanobu S, et al. MicroRNA-27 enhances differentiation of myeloblasts into granulocytes by post-transcriptionally downregulating Runx1. Br J Haematol 2009; 145: 412-23.
76. Rosa A, Ballarino M, Sorrentino A, et al. The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci USA 2007; 104: 19849-54.
77. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009; 106: 2735-40.
78. Bazzoni F, Rossato M, Fabbri M, et al. Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci USA 2009; 106: 5282-7.
79. Georgantas RW, III, Hildreth R, Morisot S, et al. CD34+ hematopoietic stem/progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-5.
80. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-7.
81. Bousquet M, Quelen C, Rosati R, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-506.
82. Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004; 114: 713-9.
83. Starczynowski DT, Morin R, McPherson A, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011; 117: 595-607.
84. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010; 16: 49-58.
85. Kumar M, Narla A, Nonami A, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011; 118: 4666-73.
86. Starczynowski DT, Kuchenbauer F, Wegrzyn J, et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol 2011; 39: 167-78.
87. Starczynowski DT, Karsan A,. Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q. Cell Cycle 2010; 9: 855-6.
88. Starczynowski DT, Karsan A,. Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24: 343-59.
89. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335-9.
90. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16: 59-66.
91. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-9.
92. Papaemmanuil E, Cazzola M, Boultwood J, et al. Chronic myeloid disorders working group of the international cancer genome consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-95.
93. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011; 44: 53-7.
94. Abdel-Wahab O, Levine R,. The spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell 2011; 20: 420-3.
95. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26: 542-5.
96. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012; 26: 1137-40.
97. Lasho TL, Finke CM, Hanson CA, et al SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012; 26: 1135-7.
98. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-72.
99. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/ myeloproliferative neoplasms. Blood 2011; 118: 6239-46.
100. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-8.
101. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119: 3203-10.
102. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-84.
103. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119: 3211-8.
104. Djuranovic S, Nahvi A, Green R,. A parsimonious model for gene regulation by miRNAs. Science 2011; 331: 550-3.
105. Reins J, Mossner M, Neumann M, et al. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. Leuk Res 2010; 34: 1610-6.
106. Dickstein J, Senyuk V, Premanand K, et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 2010; 107: 9783-8.
107. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-53.
108. Futterer A, Campanero MR, Leonardo E, et al. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 2005; 115: 2351-62.
109. Ma Y, Cui W, Yang J, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006; 108: 2726-35.
110. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008; 111: 4297-308.
111. Wu MY, Eldin KW, Beaudet AL,. Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J Natl Cancer Inst 2008; 100: 1247-59.
112. Chen ML, Logan TD, Hochberg ML, et al. Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood 2009; 114: 4045-53.